Standard BioTools Inc (NASDAQ: LAB) is -1.36% lower on its value in year-to-date trading and has touched a low of $1.21 and a high of $3.16 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The LAB stock was last observed hovering at around $2.17 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $2.18, the stock is 21.35% and 13.31% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.36 million and changing 0.46% at the moment leaves the stock -5.10% off its SMA200. LAB registered -16.15% loss for a year compared to 6-month loss of -6.84%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.68% gain in the last 1 month and extending the period to 3 months gives it a -13.83%, and is 17.20% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.76% over the week and 11.55% over the month.
Standard BioTools Inc (LAB) has around 539 employees, a market worth around $809.11M and $136.30M in sales. Profit margin for the company is -120.81%. Distance from 52-week low is 80.17% and -31.01% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.48%).
with sales reaching $41.3M over the same period.The EPS is expected to grow by 56.74% this year, but quarterly earnings will post 61.30% year-over-year. Quarterly sales are estimated to grow 62.80% in year-over-year returns.
Standard BioTools Inc (LAB) Top Institutional Holders
185.0 institutions hold shares in Standard BioTools Inc (LAB), with institutional investors hold 73.87% of the company’s shares. The shares outstanding are 371.15M, and float is at 359.39M with Short Float at 6.07%. Institutions hold 72.55% of the Float.
The top institutional shareholder in the company is CASDIN CAPITAL, LLC with over 63.96 million shares valued at $113.21 million. The investor’s holdings represent 17.1782% of the LAB Shares outstanding. As of 2024-06-30, the second largest holder is VIKING GLOBAL INVESTORS LP with 58.65 million shares valued at $103.81 million to account for 15.7524 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 21.75 million shares representing 5.8424% and valued at over $38.5 million, while VANGUARD GROUP INC holds 4.2981 of the shares totaling 16.0 million with a market value of $28.33 million.
Standard BioTools Inc (LAB) Insider Activity
The most recent transaction is an insider purchase by Casdin Partners Master Fund, L, the company’s Director. SEC filings show that Casdin Partners Master Fund, L bought 292,100 shares of the company’s common stock on Aug 23 ’24 at a price of $2.13 per share for a total of $0.62 million. Following the purchase, the insider now owns 53.63 million shares.
Standard BioTools Inc disclosed in a document filed with the SEC on Aug 22 ’24 that Casdin Partners Master Fund, L (Director) bought a total of 307,900 shares of the company’s common stock. The trade occurred on Aug 22 ’24 and was made at $1.96 per share for $0.6 million. Following the transaction, the insider now directly holds 53.33 million shares of the LAB stock.
Still, SEC filings show that on Aug 26 ’24, Casdin Partners Master Fund, L (Director) acquired 150,000 shares at an average price of $2.15 for $0.32 million. The insider now directly holds 53,775,821 shares of Standard BioTools Inc (LAB).
